QUALIGEN THERAPEUTICS INC QLGN 深 滬
等待開盤 09-05 09:30:00 美东时间
1.7067
-0.033
-1.91%
華盛通- 最 高1.74
- 今 開1.74
- 成交量 9603股
- 最 低 1.67
- 昨 收 1.74
- 總市值 93.58万
- 52周最高 10.45
- 市盈率 靜 --
- 換手率 1.75%
- 52周最低 1.61
- 委 比 19.30%
- 總股本 54.83万
- 歷史最高 687500.00
- 量 比 0.77
- 振 幅 4.02%
- 歷史最低 1.61
- 每 手 1
- 風險率 0.19%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Qualigen Therapeutics Secures Nasdaq Compliance Extension
The latest update is out from Qualigen Therapeutics ( ($QLGN) ). On July 23, 20...
07-29 05:47
Qualigen Announces $4.5M Private Placement Of 4,500 Shares Of Series A-3 Preferred Stock, Convertible Into 1.61M Common Shares At $2.80 Each
Qualigen Therapeutics, Inc. (NASDAQ:QLGN) ("Qualigen" or the "Company"), a life sciences company focused on developing platform treatments for adult and pediatric cancers with the potential for orphan drug designations,
07-29 00:43
Qualigen Therapeutics Provides Update on Nasdaq Communications and Continued Listing Status
Qualigen Therapeutics, Inc. (NASDAQ: QLGN) received two communications from Nasdaq regarding compliance issues. The company failed to meet the $2.5 million stockholders' equity requirement but regained compliance through a $4.5 million private placement. Nasdaq accepted the company's extension request to address three items: filing its 10-Q, achieving equity compliance, and demonstrating a plan to maintain compliance. The company remains committe...
07-28 21:20
Qualigen Therapeutics Announces $4.5 Million Private Placement of Series A-3 Convertible Preferred Stock
Qualigen Therapeutics, Inc. announced the completion of a private placement of Series A-3 Preferred Stock, issuing 4,500 shares for gross proceeds of $4.5 million. The shares are initially convertible into 1,607,143 common shares at $2.80 per share. Proceeds will be used for working capital. Univest, LLC acted as the exclusive agent. The offering was conducted under Regulation D, and the company plans to file a resale registration statement withi...
07-28 16:41
Qualigen shares are trading higher after the company announced it was granted patent titled "Substitued Naphthalene Diimides and Their Use." that covers 25 countries.
Qualigen shares are trading higher after the company announced it was granted p...
07-16 23:16
Qualigen Therapeutics Secures Global Patents for QN-302
Qualigen Therapeutics ( ($QLGN) ) has issued an announcement. On July 16, 2025,...
07-16 21:44
Qualigen Granted New Patents Covering 25 Countries
Qualigen Therapeutics, Inc. announced the grant of patents for its drug QN-302 in over 20 European countries, as well as in India, China, and Russia, with coverage extending into 2040. The patents, titled “Substituted Naphthalene Diimides and Their Use,” were developed by Professor Stephen Neidle and his team at University College London and licensed by Qualigen. CEO Kevin Richardson emphasized that the global patent coverage strengthens Qualigen...
07-16 12:00
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers ENDRA Life Sciences (NASDAQ:NDRA) stock increased by 50.4% to $5.2 dur...
07-08 05:06
Qualigen Therapeutics Appoints New Audit Committee Chair
Qualigen Therapeutics ( ($QLGN) ) just unveiled an update. On June 20, 2025, Qu...
06-24 23:48
Qualigen Therapeutics Faces Nasdaq Delisting Notification
Qualigen Therapeutics ( ($QLGN) ) has issued an announcement. On May 19, 2025, ...
05-20 05:48
